Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dextera Biosciences Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The current prosecution status involves 1 pending office action. This specific matter represents the full scope of the company's active engagement with the patent office at this time. The resolution of this 1 pending office action will define the portfolio's immediate progress.
The company's strategy is concentrated within 1 distinct examiner and 1 distinct art unit. This level of focus suggests that the legal team can dedicate its attention to the specific procedural requirements of an individual technical group. Because only 1 distinct art unit is involved, there is no need to coordinate across different examination divisions. The presence of 1 distinct examiner ensures that the company receives feedback from a consistent point of authority.
SABILA, MERCY HELLEN is the busiest examiner for this portfolio, currently handling 1 busiest examiner pending office action. The outcome of the company's current efforts in Biotechnology & Pharmaceuticals depends on the resolution of this specific case. Practitioners should prepare for the 1 busiest examiner pending office action by reviewing the previous rulings and preferences of SABILA, MERCY HELLEN.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17441645 | Multivalent D-Peptidic Compounds for Target Proteins | SABILA, MERCY HELLEN | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17441645 | Multivalent D-Peptidic Compounds for Target Proteins | SABILA, MERCY HELLEN | 1654 | §103 | Non-Final OA | — | Pending | Sep 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial